Myfortic (Mycophenolic Acid)

Mycophenolic acid selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for guanosine nucleotide synthesis. This limits the proliferation of T and B lymphocytes, thereby dampening the immune response that can attack a transplanted organ.

The dosage of Myfortic is individualized by the prescribing clinician based on the transplant type, patient weight, renal function, and concurrent immunosuppressants. Patients should follow the exact regimen provided by their healthcare professional.

The safety of Myfortic in pregnancy and lactation has not been definitively established. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding decisions should be made in consultation with a physician.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite, whereas alternatives like azathioprine are also antimetabolites but have different metabolic pathways. Calcineurin inhibitors such as cyclosporine act on T‑cell activation. Myfortic is often combined with calcineurin inhibitors for synergistic effect and may have a more favorable gastrointestinal profile than some alternatives.

Myfortic tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Myfortic is taken orally as a delayed‑release tablet. The tablet should be swallowed whole with water and not crushed, chewed, or split, to maintain its extended‑release properties. Dosing times are usually coordinated with other immunosuppressants as directed by the transplant team.

Serious risks include severe infections due to immunosuppression, hematologic abnormalities such as leukopenia or anemia, liver toxicity, and rare but life‑threatening conditions like progressive multifocal leukoencephalopathy (PML). Patients should report any signs of infection, unusual bruising, or liver dysfunction promptly.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should be used with caution, or avoided, in individuals with severe renal impairment, active uncontrolled infections, or those who are pregnant without a clear benefit outweighing the risk.